HRT Financial
TSHA icon

HRT Financial’s Taysha Gene Therapies TSHA Stock Holding History

HRT Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-409,254
Closed -$2.25M – 4750
2025
Q4 		$2.25M Buy
+409,254
New +$1.99M 0.01% 1229
2025
Q2 		– Sell
-139,692
Closed -$194K – 3530
2025
Q1 		$194K Buy
+139,692
New +$234K ﹤0.01% 2041
2024
Q2 		– Sell
-414,980
Closed -$1.19M – 3122
2024
Q1 		$1.19M Buy
+414,980
New +$865K 0.01% 805
2021
Q2 		– Sell
-12,239
Closed -$248K – 3541
2021
Q1 		$248K Buy
+12,239
New +$331K ﹤0.01% 2203

Other funds holding TSHA

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial's TSHA Position: Q1 2026 in Review

HRT Financial sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 409,254 shares — an estimated $2.25M sold.

HRT Financial first reported a position in TSHA in Q1 2021 and held it in 4 quarters. The position peaked at $2.25M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • HRT Financial reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 409,254 Taysha Gene Therapies shares in Q1 2026, an estimated $2.25M.
  • HRT Financial first reported a position in Taysha Gene Therapies in Q1 2021 and held it in 4 quarters.
  • HRT Financial's Taysha Gene Therapies position peaked at $2.25M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.